334970 — Prestige Biologics Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Prestige Biologics Co, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 June 30th
Period Length:	12 M	12 M	12 M	12 M	6 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-22,057	-31,033	-39,378	-49,718	-17,980
Depreciation
Amortisation
Non-Cash Items	13,555	15,727	32,453	19,835	11,157
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-6,616	-1,126	-22,865	-12,245	-1,870
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-12,309	-13,330	-25,869	-34,190	-4,450
Capital Expenditures	-8,429	-3,051	-98,011	-84,790	-19,495
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	4,880	10,211	101	1,124	18.2
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-3,549	7,160	-97,910	-83,665	-19,477
Financing Cash Flow Items	—	—	-28.4	-42.7	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	9,052	-1,179	156,312	96,463	53,979
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-6,807	-7,350	32,533	-21,392	30,052